Category: Monkey Pox Vaccine

Closeted men who have sex with men were less likely to get vaccinated or treated for Mpox than those who were out, according to a new study. Contrary to the researchers hypothesis, however, the findings suggested that the difference in vaccination rates had more to do with a lack of knowledge than with concerns about being outed.

The resource knowledge and community-connected piece seems to be implicated in that process, not outing concerns, and that was a surprise to me, said Joel Le Forestier, a postdoctoral researcher in the Department of Communication at Cornell University and the lead author of the study, which published earlier this month in the journal Psychological Science.

During the 2022 Mpox (formerly known as monkeypox) outbreak, which primarily affected men who have sex with men, Le Forestier and his colleagues recruited hundreds of sexual-minority men in Australia, Canada, the U.K, and the U.S. to complete online surveys at two points: first around the peak of the outbreak in August 2022 and then several months later after the Mpox vaccine became widely available and the outbreak waned.

Subscribe to our daily newsletter to stay ahead of the latest LGBTQ+ political news and insights.

In a press release from Cornell, Le Forestier explained that the research was inspired by a friends observation that closeted men who may not be connected to the broader LGBTQ+ community might not even know about the vaccine or where to get it. Le Forestier said that he had observed long lines of men who appeared to present as sexual minorities outside of a Toronto clinic offering Mpox vaccinations.

Im thinking, if youre in this long line of identifiably sexual minority men, and your friend walks by, youve just been outed to your friend, he said.

His friend, however, countered that closeted men might not even know those lines existed.

The only places that my friend had seen ads for Mpox vaccine clinics were in gay bars, and in the local gay village community center, Le Forestier explained. So if youre not engaging in the community in these sort of public ways, then these resources just arent getting to you.

Le Forestier and his team predicted that men who conceal their sexuality would report concerns of being outed if they sought the Mpox vaccine, and they were right. But those concerns did not necessarily correlate to lower intentions to get the vaccine.

What that suggests, Le Forestier explained, is that people who are in the closet and afraid of being outed are nonetheless saying, This is important enough to me that Im going to do it anyway.

Le Forestier said that the studys findings indicate both the benefits of being enmeshed in a community and also that more work needs to be done by public health departments to get information to marginalized groups.

Affiliating with that community and becoming a part of that community can confer some real benefits to you, he explained. Knowing about public health resources is not the only thing but its definitely one of them.

Originally posted here:

Closeted men were less likely to get the Mpox vaccine for a very surprising reason - LGBTQ Nation

Warning of uptick in mpox cases, at-risk people advised to get vaccine

by LIZ BONIS, WKRC

(Provided)

CINCINNATI (WKRC) - A warning from the Cincinnati Health Department as it sees cases climb of a potentially dangerous virus.

Just because we don't hear as much about it doesn't mean it's gone.

That's the message from public health specialists in the Tri-State who are reminding at-risk individuals to get the vaccine against monkeypox.

"It's called MPOX now, so it's not called monkeypox any longer. It's not spread by monkeys, so that's why they wanted to get away from that name and call it mpox," epidemiologist Kimberly Wright from the Cincinnati Health Department reminded people.

Wright says the CDC says it's a sexually transmitted virus and her team is putting out an alert to let people know the mpox vaccine can help stop its spread.

"There has been an uptick since last fall, we've only had three confirmed cases in people in Cincinnati, but the state did notify us that there's an uptick in our region."

You're at risk for this virus if you have been in close contact with someone with mpox.

Symptoms show up in one to four days usually and can include everything from fevers and headaches to a bad blister-like rash on the body, including on the genitals.

Getting the vaccine before symptoms show up can reduce the odds of the virus setting in.

"Primarily the spread have been with men having sex with men and then people who are immunocompromised with HIV for example are people ending up in the hospital."

Load more...

Read more here:

Warning of uptick in mpox cases, at-risk people advised to get vaccine - WKRC TV Cincinnati

The amount of people in high-risk groups getting the COVID-19 vaccine globally is "abysmal", the World Health Organisation (WHO) has warned, in a blunt message about global health threats in 2024.

From the emergence of the new JN.1 coronavirus strain, to concerns over monkeypox in central Africa, to the spread of mosquito-carried disease in new countries thanks to climate change, health looks set to hit the headlines once again next year.

As we close out 2023, we look at what the next 12 months could bring.

Sky News spoke to Dr Maria Van Kerkhove, an expert on infectious diseases, who leads the WHO's Department for Epidemic and Pandemic Preparedness and Prevention.

"I don't understand why it's a surprise," she tells Sky News, when asked about rising COVID-19 cases.

"Certainly we haven't really seen a seasonality with COVID yet. But for all of the other respiratory diseases we see an increase in the autumn and winter months in temperate regions. So it shouldn't be seen as a surprise."

This is why vaccination campaigns start early for things like influenza and COVID-19, targeting the most vulnerable, she says.

She adds: "But the vaccination coverage in all countries of the at-risk groups is abysmal

"For me, this is the biggest frustration COVID-19 actually has solutions, influenza has solutions, that can prevent severe disease and death. Why aren't we using them?"

Advertisement

Climate change and spread of Dengue fever

And it's not just coronavirus that could find itself in the spotlight over the coming year.

As global leaders gathered in Dubai to discuss the fight against climate change earlier this month, global warming was already having an effect on the spread of infectious disease, Dr Van Kerkhove says.

Dengue fever, a virus transmitted to humans by mosquitoes, is a good example.

"It really illustrates the challenges because you have the mosquitoes going further north and further south," she says.

"Countries like Italy are seeing dengue transmission within their borders that they've never experienced before."

It's thought that mosquitoes carrying dengue fever could be common in England by the 2040s.

Climate change, she says, is having an impact now.

"This is not a theoretical risk into the future. It's happening now and it has to be addressed now."

Monkeypox outbreak

Dr Van Kerkhove also pointed to an outbreak of the monkeypox virus in the Democratic Republic of the Congo, in central Africa.

"We have a huge outbreak which is now in sexual networks," she says. "Once this virus gets into sexual networks it can transmit quite efficiently between people."

Monkeypox is a disease caused by infection with the mpox virus. There are two types of the mpox virus: Clade I and Clade II.

Clade I has a higher mortality, with a fatality rate of around 10%. Clade II is generally milder, and it was this type that was circulating in Europe, Dr Van Kerkhove said.

"So we are worried about Clade I expanding to other countries, and there's very little attention on mpox right now," she explains.

She said these kinds of things don't need to be in the news every day, as long as governments themselves don't lose focus on infectious threats.

Click to subscribe to the Sky News Daily wherever you get your podcasts

Infectious disease in war zones

The world goes into 2024 with two conflicts - Ukraine-Russia and Israel-Hamas - dominating the spotlight, as well as a host of other underreported wars worldwide.

For medical professionals, the desperate conditions in war zones and the destruction of people's homes raise the risk of the spread of infectious diseases.

"It makes it that much harder," Dr Van Kerkhove says. "In addition to the infectious threats that they face, people are hungry, they're malnourished, they don't have access to clean water and waste systems and they're cold.

"People who are scared and threatened will suffer more when infectious diseases are around."

Read more: COVID strain classified 'variant of interest' Baroness Mone admits she stands to benefit from PPE contract

This is a limited version of the story so unfortunately this content is not available. Open the full version

Are we prepared for another pandemic?

The pandemic felt like it came out of nowhere.

Governments were left reeling as cases soared - with their people locked down or unable to visit suffering loved ones.

So four years later, is the world better prepared?

Yes and no, Dr Van Kerkhove says.

On the one hand, she says, she looks at capacities around the world for things like surveillance, testing and sequencing of new threats, as well as advancements in areas like infection prevention and the efforts of community health workers.

"The work in those areas put us in a much better position for the next one," she says.

But there are things that make Dr Van Kerkhove less sure about how prepared we are to tackle a new pandemic.

She explains: "I look at declining trust in the world. I look at the attacks on science and on scientists, the politicisation of every aspect of COVID."

She also argued that countries may be less willing to report a new pathogen because of financial and political incentives.

"So on my less optimistic side, I'm really concerned that in some aspects we're worse off than we were even four years ago," she adds.

Link:

'Abysmal' COVID-19 vaccine coverage, monkeypox and mosquitoes - what health threats will 2024 bring? - Sky News

FILE PHOTO: Vials of the JYNNEOS smallpox and monkeypox vaccine are placed on a table during a clinic offered by the Pima County Department of Public Health at Abrams Public Health Center in Tucson, Arizona, U.S., Aug. 20, 2022. File photo by Rebecca Noble/Reuters

KINSHASA, Congo (AP) As Congo copes with its biggest outbreak of mpox, scientists warn discrimination against gay and bisexual men on the continent could make it worse.

In November, the World Health Organization reported that mpox, also known as monkeypox, was being spread via sex in Congo for the first time. That is a significant departure from previous flare-ups, where the virus mainly sickened people in contact with diseased animals.

WATCH: Central African health workers fighting mpox face lack of vaccines and medication

Mpox has been in parts of central and west Africa for decades, but it was not until 2022 that it was documented to spread via sex; most of the 91,00 people infected in approximately 100 countries that year were gay or bisexual men.

In Africa, unwillingness to report symptoms could drive the outbreak underground, said Dimie Ogoina, an infectious diseases specialist at the Niger Delta University in Nigeria.

"It could be that because homosexuality is prohibited by law in most parts of Africa, many people do not come forward if they think they have been infected with mpox," Ogoina said.

WHO officials said they identified the first sexually transmitted cases of the more severe type of mpox in Congo last spring, shortly after a resident of Belgium who "identified himself as a man who has sexual relations with other men" arrived in Kinshasa, the Congolese capital. The U.N. health agency said five other people who had sexual contact with the man later became infected with mpox.

"We have been underestimating the potential of sexual transmission of mpox in Africa for years," said Ogoina, who with his colleagues, first reported in 2019 that mpox might be spreading via sex.

Gaps in monitoring make it a challenge to estimate how many mpox cases are linked to sex, he said. Still, most cases of mpox in Nigeria involve people with no known contact with animals, he noted.

In Congo, there have been about 13,350 suspected cases of mpox, including 607 deaths through the end of November with only about 10% of cases confirmed by laboratories. But how many infections were spread through sex isn't clear. WHO said about 70% of cases are in children under 15.

During a recent trip to Congo to assess the outbreak, WHO officials found there was "no awareness" among health workers that mpox could be spread sexually, resulting in missed cases.

WHO said health authorities had confirmed sexual transmission of mpox "between male partners and simultaneously through heterosexual transmission" in different parts of the country.

Mpox typically causes symptoms including a fever, skin rash, lesions and muscle soreness for up to one month. It is spread via close contact and most people recover without needing medical treatment.

During the 2022 major international outbreak, mass vaccination programs were undertaken in some countries, including Canada, Britain and the U.S., and targeted those at highest risk gay and bisexual men. But experts say that's not likely to work in Africa for several reasons, including the stigma against gay communities.

"I don't think we'll see the same clamoring for vaccines in Africa that we saw in the West last year," said Dr. Boghuma Titanji, an assistant professor of medicine in infectious diseases at Emory University School of Medicine in Atlanta.

She said that the gay and bisexual men most at risk of mpox might be fearful of coming forward in a broad immunization program. Countries should work on ways to give the shots if available in a way that wouldn't stigmatize them, she said.

Dr. Jean-Jacques Muyemba, general director of Congo's National Institute of Biomedical Research, said two provinces in Congo had reported clusters of mpox spread through sex, a concerning development.

There's no licensed vaccine in Congo, and it would be hard to get enough shots for any large-scale program, Muyemba said. The country is trying to get a Japanese mpox vaccine, but regulatory issues are complicating the situation, he said.

READ MORE: WHO selects 'mpox' as replacement for monkeypox, citing concerns of racism

Globally, only one vaccine has been authorized against mpox, made by Denmark's Bavarian Nordic. Supplies are very limited and even if they were available, they would have to be approved by the African countries using them or by WHO. To date, the vaccine has only been available in Congo through research.

Oyewale Tomori, a Nigerian virus expert who sits on several WHO advisory boards, said African governments probably have too many competing priorities to ask the U.N. health agency or donors for help securing vaccines.

"In Africa, mpox is most likely considered a low-priority nuisance," Tomori said.

He said stronger monitoring, laboratory networks and better availability of diagnostic supplies would be more helpful to the continent than vaccines.

Without greater efforts to stop the outbreaks in Africa, Ogoina predicted that mpox would continue to infect new populations, warning that the disease could also spark outbreaks in other countries, similar to the global emergency WHO declared last year.

"When the HIV pandemic started, it was among gay and bisexual men in the global north, and Africa thought it was not our problem," he said. "Before we knew it, it came to Africa, but we still thought heterosexual populations would be protected."

Women of reproductive age now account for more than 60% of new HIV infections in Africa.

"I worry the same thing will now happen with mpox," he said. "Unless we address these outbreaks in Africa, this virus will keep coming back."

Cheng reported from Toronto.

Visit link:

Stigma against gay and bisexual men could worsen Congos largest mpox outbreak, experts warn - PBS NewsHour

Introduction to Mpox

Mpox, also known as Monkeypox, is a relatively rare disease caused by a virus that spreads through close personal contact. It is predominantly found in Africa but has also been detected in other parts of the world. The disease presents a range of symptoms in infected individuals, which may include a rash, fever, headache, muscle pain, low energy, and swollen glands. In some severe cases, mpox can lead to secondary bacterial infections and spread to vital organs including the lungs, eyes, brain, and heart. This article aims to provide informative insights into the symptoms, transmission, and vaccination for mpox, promoting public health awareness and preparedness.

People infected with the mpox virus may experience a wide range of symptoms or only a few. Some individuals may develop flu-like symptoms, rash, and sores, while others may experience fever, lymphadenopathy, headache, backache, and myalgia either before or after the rash appears, or not at all. It is important to seek medical attention if you develop a new or unexplained rash or other symptoms that may be associated with mpox. Most people recover fully within 2 to 4 weeks, although antiviral treatments developed for smallpox may be used to prevent and manage mpox infections.

The World Health Organization (WHO) has recently confirmed the first cases of mpox caused by the clade I monkeypox virus linked to sexual contact in an outbreak in the Democratic Republic of the Congo (DRC). The virus can be transmitted to humans from different wild animals, such as nonhuman primates and rodents, although its natural host reservoir remains unknown. Mpox can also spread through cuts, lesions, and contact with mucous membranes, as well as close contact with an infected person. As the virus is more contagious and causes more severe infections than the Clade II strain, the risk of mpox spreading to neighboring countries and worldwide appears to be significant.

Vaccines are available for both pre- and post-exposure vaccination against mpox. The World Health Organization advises mass vaccination only for those at risk. In the United States, the CDC recommends vaccination for people with risk factors, with two doses of the Jynneos vaccine. Additionally, specific groups of people are eligible to receive pre-exposure vaccine as a two-dose series, with at least 28 days between the first and second doses.

The DRC is currently experiencing a significant increase in the number of reported suspected cases of mpox. The first known cases of sexual transmission of the clade I virus were reported in a small cluster of 5 cases. Meanwhile, the global mpox outbreak, which started in May 2022, is ongoing. As a result, the CDC has issued a Travel Health Notice for travelers to the Congo to minimize contact with ill people, avoid wild animals, and refrain from eating or preparing wild game. The Congo has reported over 12,500 clinically diagnosed cases and nearly 600 deaths suspected to be related to the virus.

Mpox is a serious health concern that requires global attention and awareness. With the ongoing outbreak and the potential for international spread, its crucial to understand the symptoms, transmission methods, and available prevention measures. If you experience any symptoms or have been in contact with infected individuals or animals, it is highly advised that you seek medical attention immediately.

See the rest here:

Understanding Mpox: Symptoms, Transmission, and Vaccination - Medriva

(Precision Vaccinations News)

The U.S. Centers for Disease Control and Prevention (CDC) today announced aHealth Alert Network (HAN) Health Advisoryabout the occurrence, geographic spread, and sexually associated human-to-human transmission of Clade I Monkeypox virus (MPXV) in the Democratic Republic of the Congo (DRC).

Since January 2023, the DRC has reported 12,569 suspected mpox casesand 581 related deaths from 22 regions.

The new HAN says cases of Clade I MPXV have not been reported in the United States as of December 7, 2023.The global outbreak ofClade II MPXV was initially reported in May 2022.

However, clinicians should be aware of the possibility of Clade I MPXV in travelers who have been in DRC.

Third-party dataindicate that the number of touristsarriving in the DRC wasabout 460,880in 2021.

The CDC recentlyissued aTravel Health Notice (Level 2 - Practice Enhanced Precautions) for people traveling to DRC. Furthermore,there are no direct commercial passenger flights from DRC to the U.S. as of December 2023.

U.S. FDA-approved vaccines (JYNNEOS, ACAM2000) are expected to be effective for both Clade I and II MPXV infections.

Vaccination or prior MPXV infection should provide antibodies that will provide cross-protection to other orthopoxviruses, including Clade I MPXV, says the CDC.

However, clinical verification is under review.

The CDC recommends clinicians encourage vaccination for eligible patients.

Eligible patients who have only received one dose ofBavarian NordicJYNNEOS (MVA-BN, IMVAMUNE) vaccine, which is based on a live, attenuated vaccinia virus,should receive the second dose as soon as possible, regardless of the time that has elapsed since the first dose.

Mpox vaccines have limited availability in the U.S.

Furthermore, clinicians should notify theirstate health departmentif they have a patient withmpox-like symptoms andshouldsubmit lesion specimens for clade-specific testing for these patients.

Continue reading here:

Mpox Vaccines May Work Against MPXV Clade I - Precision Vaccinations

With the world still grappling with the devastating effects of the COVID-19 pandemic, another health crisis looms. Health officials and experts are increasingly worried about the spread of a lethal strain of monkeypox, particularly in the Democratic Republic of the Congo (DRC). The virus variant, known as Clade I, is more virulent and poses a risk of human-to-human transmission. The World Health Organization (WHO) has expressed grave concerns about the outbreak and its changing epidemiology in the DRC.

The Centers for Disease Control and Prevention (CDC) has issued a health alert regarding this more lethal strain of monkeypox. The outbreak in the DRC has sickened nearly 13,000 people and caused 581 suspected deaths. Cases are believed to be spread via sexual contact, raising fears about its potential for widespread transmission. The situation in the DRC has led to a significant increase in suspected monkeypox cases and deaths, blindsiding health experts globally.

In response to this health crisis, the CDC has instructed clinicians to be vigilant and notify state health departments of any travelers with symptoms similar to monkeypox. The CDC has also emphasized the need for enhanced surveillance and testing in the United States. While there is currently no known risk for Clade I monkeypox in the United States, the CDC is not ruling out the possibility of it emerging in the future.

Countermeasures for Clade II infections, a less severe strain of monkeypox, are expected to be effective against Clade I infections. However, vaccine coverage in the U.S. remains low, with only 1 in 4 eligible people receiving both doses required for full protection. The CDC recommends people at risk for monkeypox to be vaccinated with two doses of the JYNNEOS vaccine, as two doses provide greater protection.

The response to this outbreak is being hampered by stigma, regulatory barriers, and competing disease outbreaks. This lack of urgency in providing vaccines and treatments is reminiscent of the unequal access to vaccines experienced during the COVID-19 pandemic. Concerns about discrimination, particularly in the context of sexual transmission, also add to the complexity of the situation. Despite these challenges, the need for a swift and comprehensive response is imperative.

As the world continues to reel from the impacts of one pandemic, the potential for another is a stark reminder of the interconnectedness of our global health landscape. The situation calls for increased vigilance, improved surveillance, and a renewed emphasis on vaccination. By learning from our experiences with COVID-19 and other infectious diseases, we can hopefully prevent this outbreak from escalating into a global crisis.

Read more here:

Lethal Strain of Monkeypox Sparks Health Crisis in the DRC - Medriva

The Centers for Disease Control and Prevention (CDC) recently issued a health alert in response to the ongoing outbreak of a more severe and transmissible subtype of the monkeypox (mpox) virus, known as clade I, in the Democratic Republic of Congo (DRC). This alert seeks to prepare clinicians and public health officials in the U.S. for potential cases, despite no clade I cases being reported domestically at this time.

According to the CDC, the 2022-23 global outbreak of mpox was predominantly linked to the clade II monkeypox virus. Interestingly, this outbreak has largely affected gay and bisexual men, as well as other men who have sex with men. However, the clade I subtype, now spreading in the DRC, is raising serious concerns due to its increased transmissibility and severity.

This subtype of the disease has seen a significant surge in its suspected cases and related deaths in the DRC, primarily spreading through sexually associated human-to-human contact.

The CDC has emphasized that the Jynneos mpox vaccine should be effective against both clade I and clade II mpox viruses. However, vaccination coverage in the U.S. remains low. As of now, only one in four people eligible for the vaccine have received the two doses necessary for optimum protection.

Health authorities have recommended travelers to the DRC to be cautious. The CDC advises avoiding close contact with ill or dead animals and promotes enhanced surveillance efforts, especially if the clade I strain is detected in the U.S. Additionally, clinicians are urged to be alert for patients presenting with lesions consistent with mpox.

The World Health Organization (WHO) has expressed great concern over the ongoing outbreak in the DRC, which has proved fatal for nearly 600 people, primarily children, this year. The WHO, in collaboration with Congolese authorities, is currently working on the response and conducting a risk assessment.

Furthermore, CDC and WHO are increasingly concerned about an outbreak among sex workers in South Kivu, DRC. Efforts are being made to work with the Congolese government to procure or accept donations of mpox vaccines.

In light of this health alert, it is crucial that clinicians, public health officials, and individuals who are at risk or are traveling to the DRC remain vigilant. The importance of increasing vaccination coverage against the mpox virus cannot be overstated. By taking these steps, we can help to prevent the spread and severe impacts of this disease.

Read this article:

Health Alert for Monkeypox Virus Outbreak in DRC - CDC Issues Advisory - Medriva

In the heart of the Democratic Republic of Congo (DRC), a deadly outbreak of a disease known as mpox is causing turmoil and distress. The disease, also known as monkeypox, has claimed many lives, with a reported 12,569 cases and nearly 600 fatalities between 1 January and 12 November 2023. Despite the availability of vaccines and treatments, stigma, regulatory impediments, and the presence of other concurrent disease outbreaks have hindered the response to this growing health crisis.

The ongoing mpox outbreak in the DRC is caused by the monkeypox virus, which is typically transmitted to humans through bites or direct contact with an infected animals blood, body fluids, or cutaneous/mucosal lesions. Interestingly, this outbreak involves a different clade of the mpox virus that reportedly causes more severe disease. For the first time, sexual transmission of this strain is playing a significant role, particularly among men who have sex with men.

The World Health Organization (WHO) has expressed concern about the situation in Congo, warning that the current outbreak presents a significant risk of international spread. The virus spread widely outside of Africa last year, primarily among men who have sex with men. Clade 1 mpox virus, which is currently prevalent in Congo, has a higher fatality rate than the version that spread internationally last year.

Unfortunately, the response to the outbreak has been hindered by several factors. The stigma associated with the disease, particularly due to its sexual transmission, has created barriers to prevention and control. The situation is further complicated by the fact that the DRC is described as hostile to homosexual activities, which could hamper efforts to curb the spread of the disease. Additionally, regulatory hurdles and the governments lack of urgency in responding to the outbreak have been widely criticized. The DRC has not requested to buy or applied for donations of vaccines and treatments, leaving these potentially life-saving resources unused outside the country.

SIGA Technologies, a leading pharmaceutical company, suggests that its antiviral drug TPOXX may be easier to deploy compared to the vaccine. However, this treatment has not yet been approved by the U.S. Food and Drug Administration (FDA), adding another layer of complexity to the situation.

The mpox outbreak in the DRC highlights the global issue of unequal access to vaccines, a concern that has been magnified during the COVID-19 pandemic. The DRCs struggle to utilize available vaccines and treatments underscores the critical importance of addressing these disparities and improving global health infrastructure.

As the mpox outbreak in the DRC continues to unfold, it serves as a stark reminder of the urgent need for global cooperation, accessible healthcare, and the dismantling of stigma and discrimination in the face of health crises. With the right actions and global support, it is hoped that the spread of this deadly disease can be curbed and countless lives saved.

Read the original post:

Mpox Outbreak in DRC: Monkeypox Virus Causes Turmoil and Distress - Medriva

Vancouver --News Direct-- Tonix Pharmaceuticals

Tonix Pharmaceuticals CEO Dr Seth Lederman recently joined Steve Darling from Proactive to share exciting news about their COVID vaccine, TNX-1800, selected for testing in Project Next Gen, a White House initiative managed by the Department of Health and Human Services, NIH, and NIAID.

The vaccine is based on a live virus platform, providing a unique approach to waking up the immune system. Live virus vaccines, like TNX-1800, offer more durable immunity that lasts a long time and can potentially block virus transmission, addressing limitations seen in mRNA vaccines.

This choice of TNX-1800 is a testament to Tonix's nearly decade-long dedication to vaccine development. The technology platform can also be adapted to protect against other infectious diseases, such as monkeypox, smallpox, and tuberculosis, making it a versatile solution for future pandemics.

This development highlights the significance of vaccine platforms for tackling various infectious threats. Tonix's approach promises to offer more robust, long-lasting immunity and potential transmission prevention, which could revolutionize our approach to infectious disease control. The platform's adaptability positions it as a valuable tool for future vaccine strategies.

Proactive Studio

+1 347-449-0879

na-editorial@proactiveinvestors.com

View source version on newsdirect.com: https://newsdirect.com/news/tonix-pharmaceuticals-ceo-reveals-next-generation-covid-vaccine-technology-chosen-for-key-program-673655021

Original post:

Tonix Pharmaceuticals' CEO reveals next-generation COVID vaccine technology chosen for key program - Yahoo Finance